Table 1.
Characteristics of the study population according to use of osteoporosis drugs, 2005
| Study population | Non-users of osteoporosis drugs | Users of bisphosphonates | Users of calcium + vitamin D | Users of raloxifene | |
|---|---|---|---|---|---|
| Women | |||||
| n | 450,482 | 377,748 | 24,439 | 63,831 | 1,255 |
| Mean age (years ± SD) | 82.5 ± 5.4 | 82.6 ± 5.5 | 81.5 ± 4.6 | 82.6 ± 5.2 | 80.7 ± 4.4 |
| Type of residential area (n (%)) | |||||
| Urban | 299,171 (66.4) | 247,293 (65.5) | 17,307 (70.8) | 45,713 (71.6) | 1,003 (79.9) |
| Rural | 151,311 (33.6) | 130,455 (34.5) | 7,132 (29.2) | 18,118 (28.4) | 252 (20.1) |
| Mean number of other drugs (no. ± SD) | 5.4 ± 3.9 | 5.2 ± 3.8 | 6.3 ± 4.4 | 6.5 ± 4.3 | 5.8 ± 4.2 |
| Men | |||||
| n (%) | 280,623 | 270,965 | 2,478 | 8,799 | – |
| Mean age (years ± SD) | 81.4 ± 4.9 | 81.4 ± 4.9 | 80.9 ± 4.3 | 82.0 ± 4.8 | |
| Type of residential area (n (%)) | |||||
| Urban | 180,921 (64.5) | 174,197 (64.3) | 1,685 (68.0) | 6,177 (70.2) | |
| Rural | 99,702 (35.5) | 96,768 (35.7) | 793 (32.0) | 2,622 (29.8) | |
| Mean number of other drugs (no. ± SD) | 5.1 ± 3.7 | 5.0 ± 3.7 | 7.1 ± 4.4 | 7.1 ± 4.3 | |